bowel cancer
Boehringer Ingelheim and Simcere announce inflammatory bowel disease collaboration
There are more than three million people affected by IBD globally, with a need to improve current treatments
Lilly’s Omvoh shows improved outcomes in ulcerative colitis
The phase 3 trial results demonstrated improved symptomatic, clinical and quality-of-life measures
Abivax shares positive late-stage results for obefazimod in ulcerative colitis
Inflammatory bowel disease affects nearly one in every 100 people in the US
J&J’s Tremfya approved by MHRA to treat Crohn’s disease and ulcerative colitis
Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK
Johnson & Johnson shares long-term results for Tremfya in ulcerative colitis
More than 2.5 million people in Europe are affected by the inflammatory bowel disease
Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults
More than 2.5 million people in Europe are living with the inflammatory bowel disease
J&J’s Stelara granted EC approval to treat Crohn’s disease in paediatric patients
Approximately 25% of cases are diagnosed during childhood or adolescence
Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease
Inflammatory bowel disease is estimated to affect nearly two million people across Europe
Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease
An estimated three million people in the US are affected by inflammatory bowel disease
J&J receives three CHMP recommendations for immunology and oncology indications
Tremfya, Stelara and Darzalex have been recommended for ulcerative colitis, Crohn’s disease and multiple myeloma, respectively
J&J’s shares positive results for subcutaneous Tremfya in phase 3 ulcerative colitis trial
Inflammatory bowel disease affects almost one in every 100 people in the US
Eli Lilly shares two-year results for Omvoh in active Crohn’s disease patients
Inflammatory bowel disease affects almost one in every 100 people in the US